Ariad stock options

Ariad Pharma Could Draw M&A Fire Ahead Of Second Cancer Drug.

for $24 Per Share is Fair to Shareholders - ARIA ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally.

Ariad ARIA Stock Will It Continue To Climb? CNA Finance

It now costs $199,000 a year, before factoring in insurance or any discounts. When it was first approved in 2012, the drug cost $9,580 a month. Along the way, the drug has had some safety problems and actually got pulled off the market in 2013 by the FDA, but a few months later was reinstated with warnings about cardiovascular problems that may occur.

<u>Ariad</u>'s .2 Billion Sale To Takeda Nets 0 Million Windfall For.

ARIAD Pharmaceuticals, Inc. - Investor Relations Solutions

Covers all compensation-like awards that don't fit in any of these other standard categories.

Ariad Pharmaceuticals Plummets 70% as Drug Trial Held - Stocks to.

In a research report Wednesday, RBC analysts list Ariad Pharmaceuticals (ARIA), Spark Therapeutics (ONCE), Bio Marin Pharmaceutical (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular Therapies (ITCI), Tesaro (TSRO), Incyte (INCY) and Puma Biotechnology (PBYI) -- as well as Sarepta — as top takeover contenders, all on their late-stage or FDA-approved "blockbuster franchises." Sarepta stock rocketed 74% on Monday after the FDA approved its drug to treat Duchenne muscular dystrophy, the first drug approved to treat the rare disease. After the close, Sarepta announced plans to offer up to $225 million in stock to finance further trials, production and other drug efforts. Over the past 10 months, four biotech acquisitions valued at over $5 billion have been announced, RBC said, along with a smattering of smaller deals.

Ariad stock options:

Rating: 93 / 100

Overall: 89 Rates